UNH

Research snapshot

• Overall rating: 74/100, moderately bullish
• Market-cap class: Mega cap
• Primary view: Pricing, medical-cost management, and Optum improvement are driving a sharp earnings recovery, but member losses, reserve development, Medicare funding, regulation, and government investigations require a larger risk discount
• Data date: Quarter ended June 30, 2026; technical data updates after every completed daily candle

The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.

1. Company overview

UnitedHealth Group operates two connected health-care platforms:

• UnitedHealthcare: Employer, individual, Medicare, Medicaid, and supplemental health-benefit plans.
• Optum: Care delivery, pharmacy benefits, health technology, analytics, consulting, payments, and other services.

UnitedHealthcare earns premiums and service fees for arranging and financing care. Optum Health operates or supports provider groups and value-based care. Optum Insight sells software, analytics, consulting, and revenue-cycle services. Optum Rx manages pharmacy benefits and specialty prescriptions.

The integrated model creates scale, data, distribution, and opportunities to coordinate benefits, pharmacy, technology, and care. It also creates regulatory and conflict-of-interest concerns because the company participates in many parts of the health-care system.

2. Fundamentals

Growth and profitability

Second-quarter revenue was $112.03 billion, approximately flat year over year. Earnings from operations increased to $7.99 billion from $5.15 billion, and net margin improved to 4.9% from 3.1%. GAAP EPS increased to $6.04 and adjusted EPS reached $6.38.

The medical care ratio improved to 86.7% from 89.4%. The result included $860 million of favorable prior-period reserve development, with most related to 2026 dates of service. Investors should separate genuine pricing and medical-management improvement from reserve timing.

UnitedHealthcare revenue was $86.0 billion and operating earnings improved to $3.9 billion from $2.1 billion. However, medical membership declined to 48.5 million, down 525,000 sequentially. Medicare Advantage membership has contracted by 965,000 since year end.

Optum revenue declined to $65.7 billion from $67.2 billion, but operating earnings increased to $4.0 billion from $3.1 billion and margin expanded to 6.2%. Optum Health improved despite serving fewer value-based-care patients, Optum Insight benefited from operational improvement and contract timing, and Optum Rx produced modest earnings growth.

Management raised full-year adjusted EPS guidance to $19.50 to $20.00, operating-earnings guidance above $25.45 billion, and operating cash-flow guidance to approximately $24 billion.

Balance sheet and cash flow

• Cash and short-term investments totaled $31.47 billion.
• Current and long-term debt totaled approximately $73.33 billion.
• Debt to capital improved to 41.2%, with a year-end target near 40%.
• First-half operating cash flow was $19.96 billion.
• Purchases of property, equipment, and capitalized software were $1.56 billion.
• Estimated first-half free cash flow was approximately $18.40 billion.
• UnitedHealth paid $4.09 billion in dividends during the first half.
• The company had repurchased $4.0 billion of stock through mid-July and expects at least $5.0 billion for the year.

Cash generation is strong, but the insurance subsidiaries must maintain regulatory capital. Debt, acquisitions, legal exposures, and shareholder returns compete for holding-company cash.

Valuation

Near $407 per share, UnitedHealth's equity value was approximately $370 billion. The stock traded near 30.7 times trailing earnings, but only about 20.6 times the midpoint of 2026 adjusted EPS guidance.

The forward adjusted multiple is reasonable if medical-cost improvement and updated guidance prove durable. The valuation is less attractive if favorable reserve development, portfolio actions, or temporary cost measures account for too much of the rebound. My view is reasonable recovery valuation with above-average uncertainty.

3. Technical analysis

UnitedHealth's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after every completed daily candle. Health insurers can gap on medical-cost updates, Medicare rates, legal news, regulation, and guidance.

The strongest setup requires price above the 50-day and 200-day averages, a positive EMA structure, and breakouts supported by stronger volume. Because policy and legal events can override technicals, position sizing should account for overnight gap risk.

4. Smart money concepts

The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and nearby liquidity zones using completed daily candles. These zones are technical references and do not predict regulatory, legal, or medical-cost events.

5. Growth drivers and catalysts

• Pricing discipline: Better alignment between premiums and medical costs can restore benefit margins.
• Medical management: Product design, care coordination, and operating improvement can reduce avoidable costs.
• Optum recovery: Better execution across care delivery, technology, and pharmacy can expand margins.
• Value-based care: Long-term growth can continue if Optum improves patient economics and provider relationships.
• Technology and AI: Coding, prior authorization, claims, analytics, and consumer tools can reduce administrative cost.
• Pharmacy transparency: A fee-based Optum Rx model may improve trust and align incentives.
• Prior-approval reform: Simplification may improve provider relationships and consumer experience.
• Capital returns: Strong cash flow supports debt reduction, dividends, and repurchases.

The main checkpoints are the medical care ratio, reserve development, membership, Medicare Advantage pricing, Optum Health margins, Optum Insight contracts, Optum Rx reform, cash flow, debt, investigations, and updated guidance.

6. Risks

• Medical-cost estimation: Premiums are set before the full cost of care is known.
• Reserve development: $860 million of favorable development helped the latest medical-cost result.
• Membership contraction: Medicare Advantage, Medicaid, and value-based-care populations have declined.
• Medicare funding: Multi-year rate and risk-model changes pressure benefits, pricing, and margins.
• Government investigations: UnitedHealth is subject to investigations, audits, subpoenas, and reviews from multiple agencies.
• Risk adjustment: Coding practices and Medicare payments face audits and False Claims Act litigation.
• Vertical integration: Ownership across insurance, pharmacy, care, and technology creates antitrust and conflict concerns.
• PBM regulation: Rebate, spread-pricing, and transparency reforms can change Optum Rx economics.
• Cybersecurity: The Change Healthcare attack demonstrated the financial and operational impact of a major breach.
• Provider relationships: Prior authorization, reimbursement, and network policies can create political and commercial backlash.
• Execution: Leadership changes, portfolio exits, restructuring, and acquisitions increase operating complexity.
• Debt: More than $73 billion of debt reduces flexibility if cash flow or ratings weaken.

7. Scorecard and final view

• Fundamentals: 82/100
• Growth and catalysts: 78/100
• Valuation: 70/100
• Technicals: 75/100
• Risk control: 55/100
• Overall: 74/100

Final view: UnitedHealth earns a moderately bullish 74 because pricing, medical-cost management, Optum improvement, cash flow, and raised guidance support a real recovery. Membership losses, reserve timing, Medicare funding, investigations, PBM reform, cybersecurity, and debt keep the risk discount elevated.

Sources and methodology

• UnitedHealth Q2 2026 earnings release filed with the SEC
• UnitedHealth Q1 2026 Form 10-Q and risk disclosures
• Price snapshot from Finnhub. Valuation estimates use the market price and company-reported financials. The live technical panel recalculates from the latest completed daily market candle.

Eli Lilly and Company

Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.

Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.